Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 13/20 | 0.76 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.70 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.70 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.70 |
| ▸ | LDHA | P00338 | 1/20 | 0.70 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.70 |
| ▸ | FBP1 | P09467 | 1/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.70 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.70 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.70 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.70 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432628 | 0.94 | RNASEL (0.67) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| Adenosine Phosphate SCHEMBL28920925 | 0.94 | P2RY1 (0.80) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| Adenosine Phosphate SCHEMBL29390023 | 0.94 | P2RY1 (0.80) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29354270 | 0.93 | RNASEL (0.65) | RNASELADORA1 | |
| Adenosine Phosphate SCHEMBL6264787 | 0.92 | P2RY1 (0.73) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL6689687 | 0.92 | P2RY1 (0.74) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL21527728 | 0.92 | RNASEL (0.63) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL20604358 | 0.92 | RNASEL (0.63) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL21837529 | 0.92 | RNASEL (0.63) | RNASELDNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL21527725 | 0.92 | RNASEL (0.63) | RNASELDNPH1PRKAB2TRPM2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| US-6500652-B2 | OLIGONUCLEOTIDE OF >/=4 NUCLEOTIDES THAT HAS A VIRAL NUCLEIC ACID SEQUENCE WHICH INCLUDES THE INITIATION NUCLEOTIDE | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020103143-A1 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. | 2002-08-01 | — | — | US | disclosed |
| EP-1098969-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004141-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999049085-A9 | USE OF A VIRAL POLYMERASE TO AMPLIFY NUCLEIC ACIDS | ADVANCED RES & TECH INST (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999049085-A1 | USE OF A VIRAL POLYMERASE TO AMPLIFY NUCLEIC ACIDS | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999049031-A1 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | RNASEL 4339/4885DNPH1 2457/4885PRKAB2 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.